title: [Efficacy of Derinox assessed with one PNIF (Peak Nasal Inspiratory Flow) in patients suffering from common cold].
abstract: OBJECTIVE
  The aim of this study was to compare the efficacy and tolerance of Dérinox (D) to Rhinofluimucil (R) and placebo (P) in the treatment of common cold, using an objective measure of nasal obstruction, the Peak Nasal Inspiratory Flow (PNIF--Clement Clarke International, Harlow, Angleterre).
  
  
  METHODS
  This randomized, double-blind, double-dummy, parallel group study enrolled 354 patients (34 P, 165 D et 155 R) included by 85 general practitioners. The treatment duration was 5 days at usual recommended dosage regimens. PNIF measures were done before drug administration (T0) as well as 15 min and 3 h after each intake. Moreover, nasal obstruction, rhinorrhea and global discomfort were subjectively assessed.
  
  
  RESULTS
  The efficacy of D was superior to that of P and R when comparing PNIF from T0 to T3 h after the first intake. At T15 min, rhinorrhea was significantly improved with both active treatments and global discomfort was significantly improved with D only. Treatment tolerance was satisfactory and comparable between the 3 groups.
  
  
  CONCLUSIONS
  Efficacy of Dérinox(R) was superior to that of P and R for the improvement of the nasal obstruction (PNIF) between T0 and T3h (main criteria) after the first intake in patients suffering from common cold.
authors.affiliation: Hôpital Intercommunal, 40 rue de Verdun--94000 Créteil, France.
authors.forename: R
authors.initials: R
authors.lastname: Peynegre
authors.forename: J-Fr
authors.initials: JF
authors.lastname: Dessanges
authors.forename: J
authors.initials: J
authors.lastname: Bruhwyler
authors.forename: V
authors.initials: V
authors.lastname: Concas
mesh_terms: D000111:Acetylcysteine / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000588:Amines / Q000627:therapeutic use*; D004311:Double-Blind Method; D004338:Drug Combinations; D005260:Female; D006801:Humans; D001239:Inhalation; D008297:Male; D008875:Middle Aged; D009278:Naphazoline / Q000627:therapeutic use*; D014663:Nasal Decongestants / Q000627:therapeutic use*; D015508:Nasal Obstruction / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D011239:Prednisolone / Q000627:therapeutic use*; D012129:Respiratory Function Tests; D012220:Rhinitis / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000821:virology
chemical_list: D000588:Amines; D004338:Drug Combinations; D014663:Nasal Decongestants; C101226:rhinofluimucil; D011239:Prednisolone; D009278:Naphazoline; D000111:Acetylcysteine